Balyasny Asset Management
ROIV icon

Balyasny Asset Management’s Roivant Sciences ROIV Stock Holding History

Balyasny Asset Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-273,238
Closed -$5.93M – 3438
2025
Q4 		$5.93M Buy
+273,238
New +$5.39M 0.01% 1306
2025
Q3 		– Sell
-969,979
Closed -$10.9M – 3394
2025
Q2 		$10.9M Buy
+969,979
New +$10.5M 0.02% 930
2024
Q3 		– Sell
-375,411
Closed -$3.97M – 3102
2024
Q2 		$3.97M Buy
+375,411
New +$4.11M 0.01% 1276
2024
Q1 		– Sell
-360,551
Closed -$4.05M – 3048
2023
Q4 		$4.05M Buy
+360,551
New +$3.51M 0.01% 1194
2022
Q4 		– Sell
-1,753,210
Closed -$5.64M – 3168
2022
Q3 		$5.64M Buy
1,753,210
+1,437,970
+456% +$5.57M 0.02% 933
2022
Q2 		$1.28M Buy
+315,240
New +$1.25M ﹤0.01% 1648

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Balyasny Asset Management's ROIV Position: Q1 2026 in Review

Balyasny Asset Management sold out of Roivant Sciences (ROIV) in Q1 2026, closing a stake of 273,238 shares — an estimated $5.93M sold.

Balyasny Asset Management first reported a position in ROIV in Q2 2022 and held it in 6 quarters. The position peaked at $10.9M in Q2 2025. 439 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • Balyasny Asset Management reported no remaining Roivant Sciences position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 273,238 Roivant Sciences shares in Q1 2026, an estimated $5.93M.
  • Balyasny Asset Management first reported a position in Roivant Sciences in Q2 2022 and held it in 6 quarters.
  • Balyasny Asset Management's Roivant Sciences position peaked at $10.9M in Q2 2025.
  • 439 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.